



CORRECTION

Correction: Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer

Mei Gao, Miranda Lin, Richard A. Moffitt, Marcela A. Salazar, Jinha Park, Jeffrey Vacirca, Chuan Huang, Kenneth R. Shroyer, Minsig Choi, Georgios V. Georgakis, Aaron R. Sasson, Mark A. Talamini and Joseph Kim

British Journal of Cancer (2020) 123:495; <https://doi.org/10.1038/s41416-020-0879-6>

Correction to: *British Journal of Cancer* (2019) **120**, 88-96; <https://doi.org/10.1038/s41416-018-0298-0>, published online 31 October 2018

The original version of this article contained an error in Fig. 1b. The third row should have been labelled as “PD-1” instead of “PD-L1”. The correct figure is below.




Fig. 1 Immune checkpoint expression on PDACs. a Western blot assay revealed positive immunostaining for PD-1 in MIAPaCa-2 and PANC-1 cells. Jurkat cells and PD-1 overexpression cell lysate were used as positive controls. Negative control was empty vector cell lysate. β-actin was used for loading control. **b** Immunofluorescent staining was performed for PD-1 and PD-L1 expression in MIAPaCa-2 and PANC-1 cells. Positive PD-1 and PD-L1 immunostaining was observed in both cell lines. Merged images with DAPI nuclear stains were also constructed for both PD-1 and PD-L1. **c** Immunofluorescence was performed to assess expression of PD-1 and PD-L1 in 3 PDAC PDOs. PD-1 and PD-L1 immunostaining was observed for both patients 1 and 3. However, PD-1 immunostaining was absent in PDOs from patient 2. The second row was a merge with DAPI nuclear staining.